Anivive Lifesciences is at the forefront of transforming pet health through innovative technologies that enhance veterinary care and treatment options. Their specialty diagnostics and pathology services are designed to elevate the standard of care in veterinary oncology, utilizing advanced techniques and expert insights to ensure optimal patient outcomes. The company employs SearchLight DNA, a next-generation tumor genotyping technology that facilitates personalized treatment plans for pets, particularly in the context of cancer care. Additionally, Anivive is actively developing a novel vaccine for Valley Fever, a fungal disease affecting pets, and is leveraging extensive research and data analytics to address unmet therapeutic needs in veterinary medicine.

The company’s integrated platform, ANIVIVE OS, streamlines the discovery and development of new therapeutics by harnessing real-time data and advanced analytics. This platform allows for the rapid identification of promising drug candidates while reducing the risk of failed programs. Anivive's commitment to improving pet health is further exemplified by their AI-powered tools that analyze vast datasets, including over one billion datapoints, to inform treatment strategies. Their marketplace for clinical studies enhances access to innovative therapies, enabling pet owners to participate in trials more efficiently. Overall, Anivive Lifesciences is dedicated to revolutionizing pet healthcare through cutting-edge technology and research-driven solutions.

United States

Anivive is focused on reshaping pet healthcare by bringing together experts in software development, veterinary medicine, and clinical research to accelerate the development of novel therapeutics.

Anivive. Smarter for pet health.

Anivive Lifesciences

Company Details